Disease · HP_0200042

Skin ulcer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Skin ulcer. Diseases, record HP_0200042. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0200042

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Skin ulcer; Open Targets
Open Targets ID: HP_0200042; Open Targets
Other names: Open skin sore; Open Targets
NCI Thesaurus: C54247; NCI Thesaurus
Highest stage of its drugs: Approval, for 15 of its 19 drugs, from ATC; Open Targets

Drugs19

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BECAPLERMIN	CHEMBL1201556	Protein	Approval	ATC	3	1	1	Drugs and targets
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	CHEMBL2108709	Enzyme	Approval	ATC	2	0	0	Drugs and targets
BEREMAGENE GEPERPAVEC	CHEMBL4594328	Gene	Approval	ATC	1	0	0	Drugs and targets
BIRCH TRITERPENES	CHEMBL4650246	Small molecule	Approval	ATC	1	0	0	Drugs and targets
BROMELAINS	CHEMBL2109027		Approval	ATC	1	0	0	Drugs and targets
CADEXOMER IODINE	CHEMBL2108938	Small molecule	Approval	ATC	1	0	0	Drugs and targets
CALCIUM PANTOTHENATE	CHEMBL1901349	Small molecule	Approval	ATC	1	0	0	Drugs and targets
CRILANOMER	CHEMBL2108183	Small molecule	Approval	ATC	1	0	0	Drugs and targets
DEXPANTHENOL	CHEMBL1200979	Small molecule	Approval	ATC	1	0	0	Drugs and targets
DEXTRANOMER	CHEMBL2108201	Small molecule	Approval	ATC	1	0	0	Drugs and targets

1 to 10 of 19

See all 19 drugs

Targets30

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
COL11A1	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/1301	Drugs and targets
COL11A2	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/1302	Drugs and targets
COL15A1	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/1306	Drugs and targets
COL18A1	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/80781	Drugs and targets
COL1A1	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/1277	Drugs and targets
COL1A2	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/1278	Drugs and targets
COL24A1	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/255631	Drugs and targets
COL27A1	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/85301	Drugs and targets
COL28A1	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/340267	Drugs and targets
COL2A1	Collagen	1	Collagen hydrolytic enzyme	Approval	https://conductscience.org/library/genes/1280	Drugs and targets

1 to 10 of 30

See all 30 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00593567	Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer	Phase 2	70	2022-05-31	Diabetic Foot Ulcer	GENTAMICIN, LEVOFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT00659646	The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers	Phase 2	56	2021-08-30	Diabetic Foot Ulcer	GENTAMICIN, LEVOFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT00537290	A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome	Phase 2	19	2017-10-31	Antiphospholipid Syndrome	RITUXIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00970697	Becaplermin Gel for MARTORELL's Hypertensive Leg Ulcers	Phase 3	64		MARTORELL'S ULCER, Hypertensive Leg Ulcer, Necrotic Angiodermatitis	BECAPLERMIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02600390	SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer	Phase 2	10		Leg Ulcer	PEGYLATED CARBOXYHEMOGLOBIN (BOVINE)	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Gentamicin Sponge vs Levofloxacin: deaths from any cause	0 of 47	0 of 22	69	NCT00593567	Trial comparisons
Gentamicin Sponge vs Levofloxacin: serious adverse events	0 of 47	0 of 22	69	NCT00593567	Trial comparisons
Gentamicin Sponge vs Levofloxacin: deaths from any cause	0 of 38	0 of 18	56	NCT00659646	Trial comparisons
Gentamicin Sponge vs Levofloxacin: serious adverse events	5 of 38	1 of 18	56	NCT00659646	Trial comparisons
Gentamicin Sponge vs Levofloxacin: Number of Participants With a Clinical Outcome of Clinical Cure	14 of 34	7 of 15	49	NCT00593567	Trial comparisons
Gentamicin Sponge vs Levofloxacin: Number of Participants With a Clinical Cure at Visit 3 (Day 7)	0 of 26	3 of 10	36	NCT00659646	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
23124321	RESULT	1	PubMed
22659765	RESULT	1	PubMed
22269862	DERIVED	1	PubMed
21482863	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0200042

GET https://conductscience.org/api/diseases/v1/HP_0200042/targets?page=2

API reference For AI assistants